Tempest Therapeutics | Targeted and Immune-Mediated Cancer …
WEBAug 23, 2024 · Tempest Therapeutics is developing first-in-class small molecule product candidates with broad potential benefit to patients. Innovative Targeted and Immune-Mediated Cancer Therapies Pipeline
Tempest Therapeutics, Inc. (TPST) - Yahoo Finance
WEBTempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors.
Tempest Reports Inducement Grants Under Nasdaq Listing Rule …
WEB1 day ago · Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with ...
Tempest Further Strengthens Leadership Team with Appointment …
WEB4 days ago · Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with ...
News Release Details - Tempest Therapeutics
WEBBRISBANE, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today announced positive feedback from its end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for ...
News Release Details - Tempest Therapeutics
WEBBRISBANE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class 1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced new and updated positive results from the planned data analysis of an ongoing global randomized Phase ...
Tempest Reports Second Quarter 2024 Financial ... - Tempest Therapeutics
WEBAug 8, 2024 · About Tempest Therapeutics. Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs …
About Tempest Therapeutics
WEBTempest Therapeutics is a clinical-stage biotechnology company that develops small molecule therapeutics designed to effectively treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.
Tempest Announces Successful End-of-Phase 2 Meeting with FDA …
WEBBRISBANE, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated...
Pipeline | TPST-1120 | TPST-1495 | TREX-1 | Tempest Therapeutics
WEBTempest is developing a first-in-class oncology pipeline of small molecule therapeutics with broad potential. The product candidates are designed to treat cancer by direct tumor killing, activating tumor-specific immunity, or a combination of both mechanisms.